Article
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.
The pharmacogenomics journal - 1 Sept 2018
Vujkovic Marijana, Bellamy Scarlett L, Zuppa Athena F, Gastonguay Marc R, Moorthy Ganesh S, Ratshaa Bakgaki, Han Xiaoyan, Steenhoff Andrew P, Mosepele Mosepele, Strom Brian L, Bisson Gregory P, Aplenc Richard, Gross Robert
Abstract excerpt
Inter-individual variability in efavirenz (EFV) pharmacokinetics and dynamics is dominantly driven by the polymorphism in cytochrome P450 (CYP) isoenzyme 2B6 516G>T. We hypothesized that additional CYP polymorphisms mediate the relationship between CYP2B6 516G>T, EFV metabolism, and clinical events. We investigated 21 SNPs in 814 HIV-infected adults initiating EFV-based therapy in Botswana for population...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.